(Q37679219)

21 August 2017

1 reference

title

Farletuzumab in epithelial ovarian carcinoma (English)

1 reference

21 August 2017

2

Anil K Sood

1 reference

21 August 2017

Whitney A Spannuth

1

1 reference

21 August 2017

Robert L Coleman

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Biological Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

431-437

1 reference

21 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F14712591003592069

The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003592069

A step further in understanding the biology of the folate receptor in ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003592069

Folate receptor alpha as a tumor target in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003592069

Overexpression of folate binding protein in ovarian cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003592069

Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003592069

Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003592069

Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003592069

Morphogenics as a tool for target discovery and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003592069

Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003592069

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003592069

10.1517/14712591003592069

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference